Cerenome is trading at $1.70, down 6.08%, with no clear company-specific catalyst identified during live trading on October 13, 2026.
- Cerenome’s latest listed announcements were the October 8 Florida Blue agreement and October 6 test launch; neither is a new October 13 announcement.
- Healthcare-sector weakness may add pressure, but the sector’s reported 1.37% decline does not by itself explain Cerenome’s larger move.